Literature DB >> 22456332

Oncology trials--the elephant in the room.

Rebecca Kirk, Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22456332     DOI： 10.1038/nrclinonc.2012.33

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Role of randomized phase III trials in an era of effective targeted therapies.

Authors:  Manish R Sharma; Richard L Schilsky
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy.

Authors:  Fiona Rinaldi; Elisabeth George; Amanda I Adler
Journal:  Lancet Oncol       Date:  2012-03       Impact factor: 41.316

Review 3.  Hurdles in anticancer drug development from a regulatory perspective.

Authors:  Bertil Jonsson; Jonas Bergh
Journal:  Nat Rev Clin Oncol       Date:  2012-02-21       Impact factor: 66.675

Review 4.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

5.  The clinical trials system is broken.

Authors:  Vincent T DeVita
Journal:  Nat Clin Pract Oncol       Date:  2008-12

6.  Trial watch: phase III and submission failures: 2007-2010.

Authors:  John Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

Review 7.  Drug development and clinical trials--the path to an approved cancer drug.

Authors:  Eric H Rubin; D Gary Gilliland
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

Review 8.  Timeline: Chemotherapy and the war on cancer.

Authors:  Bruce A Chabner; Thomas G Roberts
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

9.  Disclosure of investigators' recruitment performance in multicenter clinical trials: a further step for research transparency.

Authors:  Rafael Dal-Ré; David Moher; Christian Gluud; Shaun Treweek; Jacques Demotes-Mainard; Xavier Carné
Journal:  PLoS Med       Date:  2011-12-27       Impact factor: 11.069
  9 in total
  3 in total

1.  Recruitment and retention monitoring: facilitating the mission of the National Institute of Neurological Disorders and Stroke (NINDS).

Authors:  J Roberts; S Waddy; P Kaufmann
Journal:  J Vasc Interv Neurol       Date:  2012-08

Review 2.  From drug discovery to biomarker-driven clinical trials in lymphoma.

Authors:  Anas Younes; Donald A Berry
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

3.  The combinatorial complexity of cancer precision medicine.

Authors:  Frederick Klauschen; Michael Andreeff; Ulrich Keilholz; Manfred Dietel; Albrecht Stenzinger
Journal:  Oncoscience       Date:  2014-07-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.